Bain Capital Life Sciences Investors, LLC
Reports for
Bain Capital Life Sciences Investors II, LLC
Bain Capital Life Sciences Fund II, L.P.
BCLS II Investco (GP), LLC
BCLS II Investco, LP
Bain Capital Life Sciences III General Partner, LLC
Bain Capital Life Sciences Fund III, L.P.
Bain Capital Life Sciences Opportunities III GP, LLC
Bain Capital Life Sciences Opportunities III, LP
+ 6 more
BCLS Fund III Investments GP, LLC BCLS Fund III Investments, LP Bain Capital Life Sciences IV General Partner, LLC Bain Capital Life Sciences Fund IV, L.P. Bain Capital Life Sciences Opportunities IV GP, LLC Bain Capital Life Sciences Opportunities IV, L.P.Filing Date
Global Rank
#1,463
/ 8,700
▲ 698
Top Industry
Biotechnology
78.4%
Period ended 2 months ago
Filed Aug 14, 2026 · 30d
26 quarters · since Mar 2020
Portfolio Concentration
20 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
29.6%
+6.1 pts
Top 5
64.6%
−6.8 pts
Top 10
88.0%
−0.9 pts
HHI
1,365
Diversified+17
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,682,031,132 |
Last Quarter's Activity
Export CSVTrimmed
Positions the filer reduced
7 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | −3,500,000 | 3,906,565 | $131,141,499 | |
| HTFL | Heartflow, Inc. | −2,000,000 | 8,448,158 | $247,868,955 | |
| ANNX | Annexon, Inc. | −774,943 | 4,437,731 | $25,339,444 | |
| OLMA | Olema Pharmaceuticals, Inc. | −387,989 | 7,085,249 | $88,636,464 | |
| AVIR | Atea Pharmaceuticals, Inc. | −284,999 | 2,075,639 | $9,651,721 | |
| UPB | Upstream Bio, Inc. | −266,262 | 600,949 | $4,158,567 | |
| KYTX | Kyverna Therapeutics, Inc. | −225,000 | 2,885,000 | $25,705,350 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | 635,000 | $0 | |
| No positions match the current search. | ||||
20 tracked positions ·
$1,682,031,132 total
· filing declares
21 positions · $1,682,021,456
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| KLRA |
Kailera Therapeutics, Inc.
Healthcare
|
NEW | 22,583,268 | $497,509,394 | 29.58% | |
| HTFL |
Heartflow, Inc.
Healthcare
|
Reduced | 8,448,158 | $247,868,955 | 14.74% | |
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
Reduced | 3,906,565 | $131,141,499 | 7.80% | |
| SVRA |
Savara Inc
Healthcare
|
Held | 17,600,621 | $108,419,825 | 6.45% | |
| ALKS |
Alkermes plc.
Healthcare
|
Added | 1,937,938 | $101,547,951 | 6.04% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
Held | 9,808,819 | $97,990,101 | 5.83% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Held | 2,675,509 | $92,519,101 | 5.50% | |
| OLMA |
Olema Pharmaceuticals, Inc.
Healthcare
|
Reduced | 7,085,249 | $88,636,464 | 5.27% | |
| COAG |
Hemab Therapeutics Holdings, Inc.
Healthcare
|
NEW | 1,650,000 | $60,604,500 | 3.60% | |
| CABA |
Cabaletta Bio, Inc.
Healthcare
|
Added | 17,241,445 | $53,620,893 | 3.19% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 7,967,454 | $37,208,010 | 2.21% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 362,470 | $35,333,575 | 2.10% | |
| CCCC |
C4 Therapeutics, Inc.
Healthcare
|
Held | 7,171,910 | $33,492,819 | 1.99% | |
| KYTX |
Kyverna Therapeutics, Inc.
Healthcare
|
Reduced | 2,885,000 | $25,705,350 | 1.53% | |
| ANNX |
Annexon, Inc.
Healthcare
|
Reduced | 4,437,731 | $25,339,444 | 1.51% | |
| RPID |
Rapid Micro Biosystems, Inc.
Healthcare
|
Held | 8,434,560 | $14,591,788 | 0.87% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 141,234 | $10,329,854 | 0.61% | |
| AVIR |
Atea Pharmaceuticals, Inc.
Healthcare
|
Reduced | 2,075,639 | $9,651,721 | 0.57% | |
| XLO |
Xilio Therapeutics, Inc.
Healthcare
|
Held | 664,021 | $6,361,321 | 0.38% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
Reduced | 600,949 | $4,158,567 | 0.25% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.